194 related articles for article (PubMed ID: 16189256)
1. Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin.
Viljanen AP; Virtanen KA; Järvisalo MJ; Hällsten K; Parkkola R; Rönnemaa T; Lönnqvist F; Iozzo P; Ferrannini E; Nuutila P
J Clin Endocrinol Metab; 2005 Dec; 90(12):6523-8. PubMed ID: 16189256
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
Virtanen KA; Hällsten K; Parkkola R; Janatuinen T; Lönnqvist F; Viljanen T; Rönnemaa T; Knuuti J; Huupponen R; Lönnroth P; Nuutila P
Diabetes; 2003 Feb; 52(2):283-90. PubMed ID: 12540598
[TBL] [Abstract][Full Text] [Related]
3. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.
Iozzo P; Hallsten K; Oikonen V; Virtanen KA; Parkkola R; Kemppainen J; Solin O; Lonnqvist F; Ferrannini E; Knuuti J; Nuutila P
Diabetes Care; 2003 Jul; 26(7):2069-74. PubMed ID: 12832315
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.
Hällsten K; Virtanen KA; Lönnqvist F; Janatuinen T; Turiceanu M; Rönnemaa T; Viikari J; Lehtimäki T; Knuuti J; Nuutila P
Diabet Med; 2004 Dec; 21(12):1280-7. PubMed ID: 15569129
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
Hällsten K; Virtanen KA; Lönnqvist F; Sipilä H; Oksanen A; Viljanen T; Rönnemaa T; Viikari J; Knuuti J; Nuutila P
Diabetes; 2002 Dec; 51(12):3479-85. PubMed ID: 12453903
[TBL] [Abstract][Full Text] [Related]
6. Insulin-stimulated glucose uptake in skeletal muscle, adipose tissue and liver: a positron emission tomography study.
Honka MJ; Latva-Rasku A; Bucci M; Virtanen KA; Hannukainen JC; Kalliokoski KK; Nuutila P
Eur J Endocrinol; 2018 May; 178(5):523-531. PubMed ID: 29535167
[TBL] [Abstract][Full Text] [Related]
7. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
Tiikkainen M; Häkkinen AM; Korsheninnikova E; Nyman T; Mäkimattila S; Yki-Järvinen H
Diabetes; 2004 Aug; 53(8):2169-76. PubMed ID: 15277403
[TBL] [Abstract][Full Text] [Related]
8. Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy.
Tan GD; Debard C; Funahashi T; Humphreys SM; Matsuzawa Y; Frayn KN; Karpe F; Vidal H
Diabetologia; 2005 Aug; 48(8):1585-9. PubMed ID: 15991021
[TBL] [Abstract][Full Text] [Related]
9. Metformin treatment significantly enhances intestinal glucose uptake in patients with type 2 diabetes: Results from a randomized clinical trial.
Koffert JP; Mikkola K; Virtanen KA; Andersson AD; Faxius L; Hällsten K; Heglind M; Guiducci L; Pham T; Silvola JMU; Virta J; Eriksson O; Kauhanen SP; Saraste A; Enerbäck S; Iozzo P; Parkkola R; Gomez MF; Nuutila P
Diabetes Res Clin Pract; 2017 Sep; 131():208-216. PubMed ID: 28778047
[TBL] [Abstract][Full Text] [Related]
10. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.
Karlsson HK; Hällsten K; Björnholm M; Tsuchida H; Chibalin AV; Virtanen KA; Heinonen OJ; Lönnqvist F; Nuutila P; Zierath JR
Diabetes; 2005 May; 54(5):1459-67. PubMed ID: 15855334
[TBL] [Abstract][Full Text] [Related]
11. Activin A is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes.
Chen WJ; Greulich S; van der Meer RW; Rijzewijk LJ; Lamb HJ; de Roos A; Smit JW; Romijn JA; Ruige JB; Lammertsma AA; Lubberink M; Diamant M; Ouwens DM
Cardiovasc Diabetol; 2013 Oct; 12():150. PubMed ID: 24134550
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study.
Lautamäki R; Airaksinen KE; Seppänen M; Toikka J; Luotolahti M; Ball E; Borra R; Härkönen R; Iozzo P; Stewart M; Knuuti J; Nuutila P
Diabetes; 2005 Sep; 54(9):2787-94. PubMed ID: 16123370
[TBL] [Abstract][Full Text] [Related]
13. Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients.
Hwang YC; Lee EY; Lee WJ; Cha BS; Yoon KH; Park KS; Lee MK
Metabolism; 2008 Apr; 57(4):479-87. PubMed ID: 18328348
[TBL] [Abstract][Full Text] [Related]
14. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
Tan GD; Fielding BA; Currie JM; Humphreys SM; Désage M; Frayn KN; Laville M; Vidal H; Karpe F
Diabetologia; 2005 Jan; 48(1):83-95. PubMed ID: 15619071
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
Juurinen L; Kotronen A; Granér M; Yki-Järvinen H
J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
[TBL] [Abstract][Full Text] [Related]
16. Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in nonobese and obese humans.
Virtanen KA; Lönnroth P; Parkkola R; Peltoniemi P; Asola M; Viljanen T; Tolvanen T; Knuuti J; Rönnemaa T; Huupponen R; Nuutila P
J Clin Endocrinol Metab; 2002 Aug; 87(8):3902-10. PubMed ID: 12161530
[TBL] [Abstract][Full Text] [Related]
17. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.
Natali A; Baldeweg S; Toschi E; Capaldo B; Barbaro D; Gastaldelli A; Yudkin JS; Ferrannini E
Diabetes Care; 2004 Jun; 27(6):1349-57. PubMed ID: 15161787
[TBL] [Abstract][Full Text] [Related]
18. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
19. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
Zinman B; Haffner SM; Herman WH; Holman RR; Lachin JM; Kravitz BG; Paul G; Jones NP; Aftring RP; Viberti G; Kahn SE;
J Clin Endocrinol Metab; 2010 Jan; 95(1):134-42. PubMed ID: 19875477
[TBL] [Abstract][Full Text] [Related]
20. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.
van Wijk JP; de Koning EJ; Cabezas MC; op't Roodt J; Joven J; Rabelink TJ; Hoepelman AI
Ann Intern Med; 2005 Sep; 143(5):337-46. PubMed ID: 16144892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
